Skip to main content

Table 2 The methodological quality evaluation of included literature based on AHRQ

From: A meta-analysis of the incidence rate of postoperative acute kidney injury in patients with congenital heart disease

Study

Year

A

B

C

D

E

F

G

H

I

J

K

Total Scores

Chen Ya-ke

2011

1

1

1

1

1

0

1

0

0

1

0

7

Dong Yu-fu

2005

1

1

1

1

0

1

1

0

0

1

0

7

Blinder, JJ

2017

1

1

1

1

0

0

1

0

1

1

1

8

Fuhrman, DY

2019

1

1

1

1

0

1

1

0

0

1

0

7

Garcia, RU

2020

1

1

1

1

0

0

1

0

0

1

1

7

Gil-Ruiz Gil-Esparza

2014

1

1

1

1

0

1

1

0

0

1

0

7

Hirano, D

2017

1

1

1

1

1

0

1

0

0

1

0

7

Huggins, N

2014

1

1

1

1

0

1

0

0

0

1

0

6

Joffe, R

2018

1

1

1

1

1

0

1

1

0

1

0

8

Kim, J

2020

1

1

1

1

0

1

0

0

0

1

0

6

Kimura, S

2018

1

1

1

1

1

0

1

0

0

1

0

7

Kumar, TK

2016

1

1

1

1

0

0

0

0

1

1

0

6

Kwiatkowski, DM

2017

1

1

1

1

0

1

1

0

0

1

1

8

Lee, SH

2017

1

1

1

1

1

0

1

0

0

1

0

7

Li, S

2011

1

1

1

1

0

0

1

0

0

1

0

6

Madsen, NL

2017

1

1

1

1

0

0

1

0

0

1

0

6

Mah, KE

2018

1

1

1

1

1

0

1

0

0

1

0

7

Meersch, M

2014

1

1

1

1

0

0

1

0

0

1

0

6

Miklaszewska, M

2013

1

1

1

1

0

1

1

0

0

1

0

7

Park, SK

2016

1

1

1

1

0

0

1

0

0

1

0

6

Piggott, KD

2015

1

1

1

1

1

0

1

0

0

1

0

7

Ricci, Z

2012

1

1

1

1

0

0

0

0

0

1

0

5

Ruf, B

2015

1

1

1

1

0

0

1

0

0

1

0

6

Sugimoto, K

2016

1

1

1

1

0

1

0

1

0

1

0

7

Tanyildiz, M

2017

1

1

1

1

0

0

1

0

0

1

0

6

Taylor, ML

2013

1

1

1

1

1

0

1

0

0

1

0

7

Toth, R

2012

1

1

1

1

0

0

1

0

0

1

0

6

Ueno, K

2020

1

1

1

1

0

0

1

0

0

1

0

6

Van Driest, SL

2018

1

1

1

1

0

1

1

0

0

1

1

8

Zheng, J

2013

1

1

1

1

0

0

1

0

0

1

0

6

  1. A: Define the source of information (survey, record review); B: List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications; C: Indicate time period used for identifying patients; D: Indicate whether or not subjects were consecutive if not population-based; E: Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants; F: Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements); G: Explain any patient exclusions from analysis; H:Describe how confounding was assessed and/or controlled; I: If applicable, explain how missing data were handled in the analysis; J: Summarize patient response rates and completeness of data collection; K: Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained